Compare Abeona Therapeutics Inc (ABEO) vs Wendys Co (WEN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Wendys Co — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Wendys Co trades at $7.44 (market cap $1.48B). The key difference: Wendys Co is far larger — about 4× Abeona Therapeutics Inc's market cap, and Wendys Co pays a 7.2% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | WEN | |
|---|---|---|
Market Cap | $373.32M | $1.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $11.33 |
52-Week Low | $4.17 | $6.17 |
Enterprise Value | $228.22M | $5.30B |
Dividend Yield | — | 7.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Wendy's (WEN) trades at $7.78, down 9.53% today but up significantly from recent lows amid retail-driven momentum. The stock shows strong valuation metrics with P/E of 10.26 and P/S of 0.69, while recent earnings have consistently beaten expectations. Technical indicators suggest a bullish trend with key support at $7 and resistance at $8-9 levels. Recent news highlights digital sales growth and China expansion plans as potential catalysts.
The outlook remains mixed with fundamental challenges including declining net income margins (6.77% in 2025) and negative cash flow trends offset by attractive valuation and dividend yield. Key risks include weak U.S. traffic and cost inflation, while opportunities lie in international expansion and digital initiatives. Analyst consensus leans cautious with 65% hold ratings despite recent momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
